Siegall Clay B
CIK 0001167496
President and CEODirector
Filings
28
Latest Jun 2, 2026
Issuers covered
5
Showing
28 of 28
Page 1
Track record
11 of 35 open-market trades scored (31% price coverage) - 24 issuers without price data. Returns are signed: a +10% move on a sale shows as -10% (insider was wrong).
| Horizon | Trades | Win rate | Avg | Median | Best | Worst |
|---|---|---|---|---|---|---|
| 30 days | 11 | 73% | +7.7% | +11.7% | +19.8% | -18.9% |
| 90 days | 10 | 70% | +4.8% | +3.5% | +34.3% | -19.7% |
| 180 days | 7 | 29% | +16.3% | -9.1% | +169.6% | -31.6% |
| 365 days | 7 | 71% | +70.9% | +89.9% | +187.9% | -42.0% |
Issuers
Companies where Siegall Clay B has filed
| Ticker | Issuer | Filings | Last filed |
|---|---|---|---|
| IMNM | Immunome Inc. | 11 | Mar 31, 2026 |
| SGEN | Seagen Inc. | 6 | May 13, 2022 |
| STTK | Shattuck Labs, Inc. | 6 | Jun 2, 2026 |
| TRML | Tourmaline Bio, Inc. | 4 | Oct 28, 2025 |
| NRIX | Nurix Therapeutics, Inc. | 1 | May 6, 2022 |
All filings
28 Form 4 / 4-A filings, newest first
| Filed | Top transaction | Shares | Price | Value | ||
|---|---|---|---|---|---|---|